BIO
The number of gene editing drug products in development has grown in recent years, driven by the approval of CRISPR-Cas9-based therapies and next-generation gene editing technologies [1]. CRISPR-Cas9 and other gene editing technologies facilitate the precise targeting and modification of DNA sequences, leading to a potentially revolutionary treatment option for many diseases.
However, the development and manufacturing of gene editing drugs is a complex, multistep process. At present, developers must navigate a fragmented supply chain and partner with multiple contract development and manufacturing organisations (CDMOs) to access all the components, services and expertise required to develop and manufacture these innovative therapies.
To address this challenge, ReciBioPharm recently announced a partnership with Hongene Biotech, which aims to advance gene editing development and manufacturing with end-to-end gene editing CDMO services.
The benefits of end-to-end gene editing services
Companies developing gene editing therapies usually have to partner with multiple CDMOs to access all necessary services and components. For example, they may partner with ReciBioPharm for the plasmid, messenger RNA (mRNA), lipid nanoparticle (LNP) formulation and fill-finish but would need an additional partnership to access single guide RNA (sgRNA).
The ReciBioPharm-Hongene collaboration removes the need for this extra step, bringing the production of sgRNA to ReciBioPharm’s Watertown facility using Hongene’s sgRNA synthesis technology. This approach reduces the supply chain burden on gene editing developers and provides companies with a high-quality final product.
By performing all steps under one roof, from sgRNA synthesis to fill-finish, this end-to-end gene editing CDMO solution can streamline development and manufacturing and help deliver life-changing therapies to patients.
Read the recent Q&A with World Pharma Today to learn more about the ReciBioPharm partnership with Hongene, the details of our end-to-end gene editing CDMO services and the benefits for both developers and patients.